Valmark Advisers Inc. bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,365 shares of the company’s stock, valued at approximately $370,000.
Several other hedge funds and other institutional investors have also modified their holdings of the company. LS Investment Advisors LLC boosted its stake in IDEXX Laboratories by 8.2% during the 3rd quarter. LS Investment Advisors LLC now owns 4,846 shares of the company’s stock worth $754,000 after acquiring an additional 368 shares during the last quarter. Norinchukin Bank The boosted its stake in IDEXX Laboratories by 6.2% during the 3rd quarter. Norinchukin Bank The now owns 6,495 shares of the company’s stock worth $1,010,000 after acquiring an additional 379 shares during the last quarter. Cubist Systematic Strategies LLC boosted its stake in IDEXX Laboratories by 5.3% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 7,662 shares of the company’s stock worth $1,191,000 after acquiring an additional 384 shares during the last quarter. Catalyst Capital Advisors LLC boosted its stake in IDEXX Laboratories by 2.3% during the 4th quarter. Catalyst Capital Advisors LLC now owns 17,600 shares of the company’s stock worth $2,752,000 after acquiring an additional 400 shares during the last quarter. Finally, Synovus Financial Corp boosted its stake in IDEXX Laboratories by 18.1% during the 3rd quarter. Synovus Financial Corp now owns 2,655 shares of the company’s stock worth $408,000 after acquiring an additional 406 shares during the last quarter. 86.02% of the stock is currently owned by institutional investors.
Shares of IDEXX Laboratories, Inc. (IDXX) opened at $183.16 on Wednesday. The company has a debt-to-equity ratio of -11.26, a quick ratio of 0.80 and a current ratio of 0.97. The company has a market cap of $15,970.00, a P/E ratio of 55.84, a price-to-earnings-growth ratio of 2.24 and a beta of 0.58. IDEXX Laboratories, Inc. has a fifty-two week low of $141.02 and a fifty-two week high of $198.73.
IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, February 1st. The company reported $0.77 EPS for the quarter, topping the consensus estimate of $0.73 by $0.04. The firm had revenue of $506.00 million for the quarter, compared to the consensus estimate of $490.51 million. IDEXX Laboratories had a net margin of 13.36% and a negative return on equity of 432.19%. The business’s quarterly revenue was up 14.2% on a year-over-year basis. During the same period last year, the company posted $0.58 EPS. equities analysts anticipate that IDEXX Laboratories, Inc. will post 4.09 earnings per share for the current fiscal year.
In other IDEXX Laboratories news, insider Giovani Twigge sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total transaction of $312,140.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $165.15, for a total transaction of $2,972,700.00. Following the sale, the chief executive officer now owns 1,077,112 shares in the company, valued at $177,885,046.80. The disclosure for this sale can be found here. Insiders have sold a total of 86,762 shares of company stock worth $15,202,484 over the last 90 days. Corporate insiders own 2.77% of the company’s stock.
IDXX has been the topic of several recent analyst reports. Zacks Investment Research raised shares of IDEXX Laboratories from a “hold” rating to a “strong-buy” rating and set a $214.00 price objective on the stock in a research note on Monday, February 5th. BidaskClub lowered shares of IDEXX Laboratories from a “hold” rating to a “sell” rating in a research note on Saturday, December 16th. Bank of America lifted their price objective on shares of IDEXX Laboratories from $200.00 to $220.00 and gave the stock a “buy” rating in a research note on Friday, February 2nd. Piper Jaffray Companies lifted their price objective on shares of IDEXX Laboratories to $211.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Finally, Stifel Nicolaus reissued a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $194.00.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/21/2365-shares-in-idexx-laboratories-inc-idxx-acquired-by-valmark-advisers-inc.html.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.